Turning Point Therapeutics, Inc. Soared

Turning Point Therapeutics, Inc. (TPTX:NASDAQ) jumped higher at $74.59, representing a gain of 118.4%. The stock got featured on our News Catalysts scanner on Fri, Jun 03, 2022 at 04:53 PM in the 'BIOTECH' category. From Fri, May 20, 2022, the stock recorded 37.50% Up Days and 44.44% Green Days

About Turning Point Therapeutics, Inc. (TPTX:NASDAQ)

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.